The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

Antengene’s Xpovio approved for reimbursement in Taiwan to treat adult patients with relapsed/refractory multiple myeloma: Shanghai Friday, February 14, 2025, 16:00 Hrs [IST] An ...

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in ...

BioSkryb Genomics, a Durham company focused on single-cell and ultra-low input multiomics, has introduced a new service called ResolveSEQ MRD, which allows more detailed classification and ...

1 Multiple myeloma originates in blood plasma cells ... sometimes without warning, and the mechanisms that render the disease incurable are not well understood. Many patients therefore require ...

"The developers expect to create Russia's first drug for multiple myeloma based on CAR-NK therapy ... as it allows activating the natural mechanisms of the immune response and destruction of tumor ...

Pelvital, the women's health MedTech company on a mission to transform the standard of care for urinary incontinence, announced today the publication of a landmark review paper "Transvaginal ...

CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group with a market capitalization of $14.71 million, ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood ...